Zobrazeno 1 - 10
of 61
pro vyhledávání: '"S, Bathers"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. Butler-Walley, Rachel Winstanley, Gareth Stephens, S. Bathers, M. Moffatt, Kieran Bromley, J. Denton, Linda S Chesterton, L. Dikomitis, Chris Littlewood, Nadine E Foster, S. Mehta, L. Funk, Martyn Lewis, Marcus Bateman, T. Cookson
Publikováno v:
Physiotherapy. 113:e13-e14
Autor:
Eline H. van Roekel, Richard T. Bryan, D. Michael A. Wallace, Deborah Bird, Maurice P. Zeegers, Humera Khan, Andrew Howman, Stuart Collins, Kar Keung Cheng, Janet A. Dunn, S. Bathers, Nayneeta Deshmukh, Nicholas D. James, Margaret Grant, Gulnaz Iqbal
Publikováno v:
BJU International. 112:169-175
Objectives To compare patient and tumour characteristics at presentation from two large bladder cancer cohorts, with recruitment separated by 15–20 years To identify significant differences in the West Midlands' urothelial cancer of the bladder (UC
Autor:
D, Spooner, D D, Stocken, S, Jordan, S, Bathers, J A, Dunn, C, Jevons, L, Dodson, J M, Morrison, G D, Oates, R J, Grieve, G, De Silva
Publikováno v:
Clinical Oncology. 24:697-706
Postoperative radiotherapy is routinely used in early breast cancer employing either 50 Gy in 25 daily fractions (long course) or 40 Gy in 15 daily fractions (short course). The role of radiotherapy and shorter fractionation regimens require validati
Autor:
Christopher J. Poole, Louise Hiller, I. N. Fernando, P. Harvey, Helena M. Earl, A.M. Brunt, Janet A. Dunn, David Spooner, S. Bathers, Andrew Stanley, R.K. Agrawal, S O'Reilly, Daniel Rea, Karen McAdam, R.J. Grieve
Publikováno v:
British Journal of Cancer
The NEAT trial reported considerable benefit for ECMF (epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil) of 28% for relapse-free survival (RFS) and 30% for overall survival (OS), when compared with classical CMF in early breas
Autor:
D. Michael A. Wallace, Nicholas D. James, S. Bathers, Richard T. Bryan, Tim J. Evans, Stuart Collins, Janet A. Dunn, James W.F. Catto, Gulnaz Iqbal
Publikováno v:
European urology focus. 1(1)
Background The relationship between pathway delays and bladder cancer–specific survival is complex because of the influence of tumour- and patient-specific factors. Objective To investigate the influence of tumour factors, patient factors, carcinog
Publikováno v:
BJU International. 94:539-543
OBJECTIVES To investigate the relationship between deprivation, delay and survival from bladder cancer in the West Midlands, as socio-economic deprivation is associated with worse survival in many malignancies, and it has been suggested that treatmen
Publikováno v:
BJU International. 89:868-878
Objective To assess in detail and evaluate the effect on survival of delays in the diagnosis and treatment of cancer (which might lead to a worse prognosis), dividing the delay from onset of symptoms to first treatment into several components, compri
Publikováno v:
European Urology. 38:279-286
Objectives: To establish the long–term outcome for muscle–invasive transitional cell carcinoma of the bladder treated by radiotherapy with or without neoadjuvant cisplatin.
Autor:
R.K. Agrawal, R Cf Leonard, Elena Provenzano, Peter Simmonds, Sarah Jordan, S M Crawford, Robert Grieve, S. Bathers, David Cameron, Carlos Caldas, J Ms Bartlett, Fiona M. Blows, D.W. Rea, Louise Hiller, I. N. Fernando, Karen McAdam, Sarah Bowden, P Pharoah, Janine Mansi, Helena M. Earl, David Spooner, Janet A. Dunn, Alison F. Munro, Andrew Stanley, L. Foster, Chris J. Twelves, S O'Reilly, Christopher J. Poole, A.M. Brunt, A-L Vallier
Publikováno v:
British Journal of Cancer
Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R C F, Twelves, C J, Cameron, D, Bartlett, J M S, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J 2012, ' Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials ', British Journal of Cancer, vol. 107, no. 8, pp. 1257-1267 . https://doi.org/10.1038/bjc.2012.370
Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R C F, Twelves, C J, Cameron, D, Bartlett, J M S, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J 2012, ' Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials ', British Journal of Cancer, vol. 107, no. 8, pp. 1257-1267 . https://doi.org/10.1038/bjc.2012.370
Background:\ud The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a1b6ab9c6c1ed53cf274faa0f92266
https://eprints.keele.ac.uk/3177/1/bjc2012370a.pdf
https://eprints.keele.ac.uk/3177/1/bjc2012370a.pdf